Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CK-636 is a synthetic small molecule inhibitor of the Arp2/3 complex. The Arp2/3 complex is a key actin nucleator that initiates the formation of branched actin filament networks in cells. By inhibiting this complex, CK-636 disrupts actin polymerization and has been widely used as a research tool to study cell motility and cytoskeletal dynamics. It is not approved for clinical use and is primarily utilized in laboratory settings for mechanistic studies of actin-related cellular processes[1][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CK-636.